Atlas Trials

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Clinical trial NCT07225946 · RECRUITING

Trial details

NCT number
NCT07225946
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Prostatic Neoplasms, Castration-Resistant
Start date
2025-12-19
Primary completion
2027-11-19
Enrollment
800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.